Mesenteric Ischemia Markers Study
MESMARK
1 other identifier
interventional
120
1 country
1
Brief Summary
Vascular bowel disease remains a socially significant and potentially fatal condition (if it develops into AMI), primarily due to delayed diagnosis. Blood biomarkers are theoretically ideal for early risk stratification (like troponins in myocardial infarction). However, the existing evidence base is characterized by low quality and high heterogeneity, which hinders their use in clinical practice. Therefore, there is an urgent and unmet clinical need for high-quality, methodologically rigorous research to validate biomarkers in MI. A current study (MESMARK) is to be undertaken to identify combinations of biomarkers that can reliably identify mesenteric ischemia (MI) and distinguish between non-transmural and transmural clinical relevant ischemia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Dec 2025
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 22, 2025
CompletedFirst Submitted
Initial submission to the registry
February 27, 2026
CompletedFirst Posted
Study publicly available on registry
March 10, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 12, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 12, 2026
March 10, 2026
March 1, 2026
8 months
February 27, 2026
March 4, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Increasing in the level of mesenteric ischemia (MI) markers above the reference threshold level within 1 day after enrollment in the study
Assessment of serum markers level is intended to identify reliable serum markers or the panel of them as biomarkers for the diagnosis of MI. The endpoint is "increasing in serum marker level above the threshold reference level within 24 hours of objectively suspected MI or not". Markers with elevated above the reference threshold level will be assessed individually and in combination (as a marker panel) later to calculate their sensitivity and specificity in diagnostic of MI. These markers include intestinal fatty acid-binding protein (I-FABP), alpha-glutathione S-transferase (α-GST), ischaemia-modified albumin (IMA), D-lactate, D-dimer, adropin, hypoxia-inducible factor (HIF-1α).
From enrollment to the 24 hours
Study Arms (1)
MA data and blood samples data
OTHERPatients with MA lesions and suspicion of acute or chronic vascular diseases of the intestine. Patients with suspicion of AMI or CMI are to be included and blood samples are to be collected. Blood samples is the only intervention.
Interventions
Blood samples as diagnostic tests are the only intervention in the trial
Eligibility Criteria
You may qualify if:
- years or older, all sex
- Initial decision, the presence of angio-visualisation of the MA and suspicion of mesenteric arteries diseases
- Patient's consent to participate in the study
- No pregnancy, no history of major operations on MA, the gastrointestinal tract and digestive organs (except appendectomy, endoscopic polypectomy).
You may not qualify if:
- Consent declined by patient or relatives
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Belarusian State Medical University
Minsk, Belarus
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor of the Department of Surgery and Endoscopy BSMU, MD, PhD
Study Record Dates
First Submitted
February 27, 2026
First Posted
March 10, 2026
Study Start
December 22, 2025
Primary Completion (Estimated)
August 12, 2026
Study Completion (Estimated)
December 12, 2026
Last Updated
March 10, 2026
Record last verified: 2026-03